title: [A randomized controlled study of post-operative adjuvant therapy in non-small cell lung cancer].
abstract: The efficacy of postoperative adjuvant chemo- and chemoimmunotherapy in non-small cell lung cancer was evaluated in a multicentric prospective randomized study. From September 1987 to June 1990, resected lung cancer patients were randomly stratified into three groups. Group A received 2 courses of chemotherapy with CDDP and VDS following operation. Group B was administered UFT daily for 1 year after 2 courses of CDDP. Group C received intrapleural administration of OK-432 after lung resection, then UFT and OK-432 once every 2 weeks for 1 year. Out of 94 cases, analyses were carried out on 87 of eligible cases. The five-year survival rate was 56.8% in stage I (43 cases), 73.3% in stage II (12 cases), 18.8% in stage IIIA (24 cases), 50% in stage IIIB (2 cases) and 33.3% in stage IV (6 cases). The five-year survival rate in group A was 32.2%, 55.2% in group B and 53.9% in group C, and no statistical difference was recognized between 3 groups. But in the cases of noncurative resection, the 5-year survival rate was significantly low in group A compared with Group B or C. Similarly, the cases with low-grade TP (<6.0 g/dl) or low response of PPD skin reaction (< 12mm) showed a significantly low 5-year survival rate only in group A. From these results, it was suspected that aggressive chemotherapy provides no benefit for postoperative lung cancer patients with advanced disease.
authors.affiliation: The Lung Cancer Study Group of First Department of Surgery, Hirosaki University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Fukushima
authors.forename: T
authors.initials: T
authors.lastname: Tsushima
authors.forename: H
authors.initials: H
authors.lastname: Ito
authors.forename: Y
authors.initials: Y
authors.lastname: Fukuda
authors.forename: A
authors.initials: A
authors.lastname: Maruyama
authors.forename: H
authors.initials: H
authors.lastname: Fujita
authors.forename: N
authors.initials: N
authors.lastname: Yagihashi
authors.forename: T
authors.initials: T
authors.lastname: Tsuge
authors.forename: T
authors.initials: T
authors.lastname: Ishioka
authors.forename: T
authors.initials: T
authors.lastname: Kudo
authors.forename: S
authors.initials: S
authors.lastname: Kishibe
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.forename: S
authors.initials: S
authors.lastname: Machida
authors.forename: R
authors.initials: R
authors.lastname: Kogawa
authors.forename: K
authors.initials: K
authors.lastname: Takashima
authors.forename: H
authors.initials: H
authors.lastname: Koie
authors.forename: K
authors.initials: K
authors.lastname: Fujita
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007564:Japan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000008:administration & dosage; D011446:Prospective Studies; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D010844:Picibanil; D014498:Uracil; D002945:Cisplatin; D014751:Vindesine